Monte Rosa has built a library of small molecule protein degraders that make broader use of the “degron” structures grabbed by the field’s first drugs, thalidomide derivatives. Launched from Versant Ventures’ Swiss incubator lab Ridgeline,...

Allostery company HotSpot has added strategic and crossover investors to the mix for a $65 million series B round designed to take two small molecules into the clinic, but the company believes it will still...

With $135 million up front from Roche, Vividion aims to develop more potent, durable and selective targeted protein degraders by using its covalent chemistry to engage untapped ubiquitin ligases. Targeted protein degraders typically connect one...

Amgen’s 2019 takeout of DNA-encoded library (DEL) company Nuevolution is fueling the big biotech’s move into the crowded field of targeted protein degradation. The team that drove the acquisition will also use DELs to discover...

Award swells to $1.2B, plus royalties, in Kite CAR T suit  Bristol Myers Squibb Co. (NYSE:BMY) and Memorial Sloan Kettering Cancer Center will receive at least $1.2 billion from Gilead Sciences Inc. (NASDAQ:GILD) after a...

Nurix’s $120 million funding round is the second fund-raising for a targeted protein degradation company in excess of $100 million this week. Along with Kymera’s $102 million round, Nurix’s deal reflects the promise investors see...

It’s a big year for targeted protein degraders, and Kymera is adding to the momentum with a $102 million series C round that should bring its first three programs into the clinic. Biotechnology Value Fund...

The idea of sending disease-driving proteins to the cell’s garbage can is only the first act in a field that now centers around targeted degradation. In the sequel, researchers are extending the principle to other...

DISEASE CATEGORY: Cancer INDICATION: Breast cancer Increasing the expression of RNF208, an estrogen-inducible E3 ligase, could treat metastatic triple-negative breast cancer (TNBC). RNA levels of RNF208 were lower in tumor tissue from patients with TNBC...

A big pharma deal and near-term clinical milestones provided enough grist for investors to back Bridge Biotherapeutics' IPO despite several recent setbacks for public Korean biotechs. The strategy of Bridge Biotherapeutics Inc. (KOSDAQ:288330) to translate...